Asosiy kontentga oʻtish
Maqola

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand RoutyLa Ligue Contre le CancerEmmanuelle Le ChatelierMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceLisa DerosaInstitut Gustave RoussyConnie P.M. DuongCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceMaryam Tidjani AlouGustave Roussy Cancer Campus (GRCC), Villejuif, FranceRomain DaillèreInstitut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, FranceAurélie FluckigerCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceMeriem MessaoudeneLa Ligue Contre le CancerConrad RauberUniv. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, FranceMaría Paula RobertiInstitut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, FranceMarine FidelleCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceCaroline FlamentInstitut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, FranceVichnou Poirier-ColameCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FrancePaule OpolonGustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, FranceChristophe KleinSorbonne UniversitéKristina IribarrenMetabolomics and Cell Biology Platforms, GRCC, Villejuif, FranceLaura MondragónUniversité Pierre et Marie Curie, Paris, FranceNicolas JacquelotInstitut Gustave RoussyBo QuUniv. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, FranceGladys FerrereInstitut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, FranceCéline ClémensonInstitut Gustave RoussyLaura MezquitaDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceJ. Remon MasipDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceCharles NaltetHôpital Bichat-Claude-BernardSolenn BrosseauDélégation Paris 7Courèche KaderbhaïDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceCorentin RichardDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceHira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USAFlorence LevenezMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceNathalie GalleronMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceBenoît QuinquisMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceNicolas PonsMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceBernhard RyffelCentre National de la Recherche ScientifiqueVéronique Minard-ColinDepartment of Pediatric Oncology, GRCC, Villejuif, FrancePatrick GoninGustave Roussy Cancer Campus (GRCC), Villejuif, FranceJean‐Charles SoriaDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceÉric DeutschInstitut Gustave RoussyYohann LoriotUniv. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, FranceFrançois GhiringhelliDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceGérard ZalcmanDélégation Paris 7François GoldwasserAssistance Publique – Hôpitaux de ParisBernard EscudierGustave Roussy Cancer Campus (GRCC), Villejuif, FranceMatthew D. HellmannDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAAlexander EggermontInstitut National de la Santé et de la Recherche Medicale (INSERM) U1015 and Equipe Labellisée–Ligue Nationale contre le Cancer, Villejuif, FranceDidier RaoultInsermLaurence AlbigèsDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceGuido KroemerINSERM U1138, Paris, FranceLaurence ZitvogelLa Ligue Contre le Cancer
2017en
ABI

Annotatsiya

Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

6 ta iqtibos0 ta foydalanilgan manba